With Gilead’s CEO on the way out and revenues tumbling, the company needs a leader who can pump up cancer sales. And it may have found just that in the ranks of the world's biggest cancer drug maker.
At $1.5 million, Frazier's base salary has remained steady for several years running. But his cash incentive pay more than doubled year-over-year, to $3.34 million.